JP2010017185A5 - - Google Patents

Download PDF

Info

Publication number
JP2010017185A5
JP2010017185A5 JP2009192598A JP2009192598A JP2010017185A5 JP 2010017185 A5 JP2010017185 A5 JP 2010017185A5 JP 2009192598 A JP2009192598 A JP 2009192598A JP 2009192598 A JP2009192598 A JP 2009192598A JP 2010017185 A5 JP2010017185 A5 JP 2010017185A5
Authority
JP
Japan
Prior art keywords
flavivirus
virus
antigen
subviral particle
particle according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009192598A
Other languages
English (en)
Other versions
JP2010017185A (ja
JP5236597B2 (ja
Filing date
Publication date
Priority claimed from US09/826,115 external-priority patent/US7227011B2/en
Application filed filed Critical
Publication of JP2010017185A publication Critical patent/JP2010017185A/ja
Publication of JP2010017185A5 publication Critical patent/JP2010017185A5/ja
Application granted granted Critical
Publication of JP5236597B2 publication Critical patent/JP5236597B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (21)

  1. 転写単位を含む宿主細胞から分泌されたサブウイルス粒子であって、該転写単位は、第一のフラビウイルスの構造蛋白質のシグナル配列および免疫原性フラビウイルス抗原をコードし、該抗原は、Ｍ蛋白質およびＥ蛋白質を含み、そして該抗原は第二のフラビウイルスの抗原であるかまたは該抗原は１より多くのフラビウイルスからのアミノ酸配列を含むキメラ抗原であり、そしてここで該転写単位は該抗原の合成を指示する、サブウイルス粒子。
  2. 前記第一のフラビウイルスが日本脳炎ウイルスである、請求項１記載のサブウイルス粒子。
  3. 前記シグナル配列が配列番号：１４または配列番号：２７を含む、請求項１記載のサブウイルス粒子。
  4. 前記免疫原性フラビウイルス抗原が第二のフラビウイルスの抗原である、請求項１〜３のいずれか１項記載のサブウイルス粒子。
  5. 前記第二のフラビウイルスが、黄熱病ウイルス、デング血清型１型ウイルス、デング血清型２型ウイルス、デング血清型３型ウイルス、デング血清型４型ウイルス、セントルイス脳炎ウイルス、ポワッサンウイルスおよび西ナイルウイルスからなる群より選択される、請求項４記載のサブウイルス粒子。
  6. 前記免疫原性フラビウイルス抗原がキメラ抗原である、請求項１〜３のいずれか１項記載のサブウイルス粒子。
  7. 前記キメラ抗原が前記第一のフラビウイルスおよび第二のフラビウイルスからのアミノ酸配列を含む、請求項６記載のサブウイルス粒子。
  8. 前記第二のフラビウイルスが、黄熱病ウイルス、デング血清型１型ウイルス、デング血清型２型ウイルス、デング血清型３型ウイルス、デング血清型４型ウイルス、セントルイス脳炎ウイルス、ポワッサンウイルスおよび西ナイルウイルスからなる群より選択される、請求項７記載のサブウイルス粒子。
  9. 前記免疫原性フラビウイルス抗原がキメラＥ蛋白質を含む、請求項７または請求項８記載のサブウイルス粒子。
  10. 前記免疫原性フラビウイルス抗原が、前記第二のフラビウイルス由来のＭ蛋白質と、日本脳炎ウイルスおよび前記第二のフラビウイルス由来のアミノ酸を含むキメラＥ蛋白質とを含む、請求項９記載のサブウイルス粒子。
  11. 前記キメラＥ蛋白質が、日本脳炎ウイルス由来のカルボキシ末端部分を含み、ここで該カルボキシ末端部分は、該キメラＥ蛋白質の約５％、１０％、１５％、２０％、２５％、３０％、４０％、５０％または７５％である、請求項１０記載のサブウイルス粒子。
  12. 前記カルボキシ末端部分は前記キメラＥ蛋白質の約１０％である、請求項１１記載のサブウイルス粒子。
  13. 前記カルボキシ末端部分は前記キメラＥ蛋白質の約２０％である、請求項１１記載のサブウイルス粒子。
  14. 前記第二のフラビウイルスはデングウイルスである、請求項７〜１３のいずれかに記載のサブウイルス粒子。
  15. 前記第二のフラビウイルスはセントルイス脳炎ウイルスである、請求項７〜１３のいずれかに記載のサブウイルス粒子。
  16. 前記転写単位は、前記抗原の合成を機能的に制御するように適当に配置された制御配列を含む、請求項１〜１５のいずれか記載のサブウイルス粒子。
  17. 前記転写単位によってコードされる前記抗原を含むポリペプチドについての翻訳開始部位に配置されたコザックコンセンサス配列を含む、請求項１〜１６のいずれか記載のサブウイルス粒子。
  18. 前記転写単位はポリ−Ａターミネーターを含む、請求項１〜１７のいずれか記載のサブウイルス粒子。
  19. 請求項１〜１８のいずれか記載のサブウイルス粒子および薬学的に許容される担体を含む、組成物。
  20. フラビウイルスによる感染症に対して被験者を免疫する医薬の製造における、請求項１９記載の組成物の使用。
  21. フラビウイルスによる感染症に対して被験者を免疫するための組成物であって、請求項１〜１８のいずれか記載のサブウイルス粒子および薬学的に許容される担体を含む、組成物。
JP2009192598A 2001-04-04 2009-08-21 フラビウイルス感染症の予防のための核酸ワクチン Expired - Fee Related JP5236597B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/826,115 2001-04-04
US09/826,115 US7227011B2 (en) 1998-06-04 2001-04-04 Nucleic acid vaccines for prevention of flavivirus infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002579516A Division JP4448281B2 (ja) 2001-04-04 2002-04-04 フラビウイルス感染症の予防のための核酸ワクチン

Publications (3)

Publication Number Publication Date
JP2010017185A JP2010017185A (ja) 2010-01-28
JP2010017185A5 true JP2010017185A5 (ja) 2010-10-14
JP5236597B2 JP5236597B2 (ja) 2013-07-17

Family

ID=25245753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002579516A Expired - Lifetime JP4448281B2 (ja) 2001-04-04 2002-04-04 フラビウイルス感染症の予防のための核酸ワクチン
JP2009192598A Expired - Fee Related JP5236597B2 (ja) 2001-04-04 2009-08-21 フラビウイルス感染症の予防のための核酸ワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002579516A Expired - Lifetime JP4448281B2 (ja) 2001-04-04 2002-04-04 フラビウイルス感染症の予防のための核酸ワクチン

Country Status (12)

Country Link
US (6) US7227011B2 (ja)
EP (3) EP1935991B1 (ja)
JP (2) JP4448281B2 (ja)
KR (1) KR100913984B1 (ja)
CN (2) CN1304575C (ja)
BR (1) BRPI0208301B8 (ja)
CA (1) CA2443323C (ja)
HK (1) HK1062836A1 (ja)
MX (1) MXPA03008838A (ja)
NZ (1) NZ529106A (ja)
WO (1) WO2002081754A1 (ja)
ZA (1) ZA200307580B (ja)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US20040037848A1 (en) * 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
US20050031641A1 (en) * 2001-04-06 2005-02-10 Loosmore Sheena May Recombinant vaccine against West Nile Virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
MXPA04000680A (es) * 2001-07-27 2004-04-05 Wyeth Corp Vacuna para virus west nile.
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
EP1601947A2 (en) * 2002-10-31 2005-12-07 Health Research, Incorporated Diagnostic test for west nile virus
EP2360168A1 (en) * 2002-11-08 2011-08-24 The Administrators of the Tulane Educational Fund Flavivirus fusion inhibitors
CA2432738A1 (en) * 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2004112694A2 (en) 2003-05-23 2004-12-29 Chiron Corporation Immunogenic reagents from west nile virus
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
EP1664786B1 (en) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
US20080118528A1 (en) * 2004-05-04 2008-05-22 Tsanyang Jake Liang Synthesis and Purification of West Nile Virus Virus-Like Particles
CN103088038B (zh) * 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
WO2006025990A2 (en) 2004-07-27 2006-03-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Diseases Control And Prevention Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
CA2582534A1 (en) * 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
KR101501162B1 (ko) * 2004-10-20 2015-03-16 사노피 파스테르 바이오로직스, 엘엘씨 일본 뇌염 바이러스 및 웨스트 나일 바이러스에 대한 백신
EP1863528A2 (en) * 2005-04-01 2007-12-12 Wyeth Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
EP1896069B1 (en) 2005-06-24 2013-03-13 Intervet International BV Inactivated chimeric vaccines and related methods of use
US7455842B2 (en) * 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
US20070190617A1 (en) * 2006-02-13 2007-08-16 Chang-Jer Wu DNA vaccine for Japanese encephalitis virus
US20080044808A1 (en) * 2006-08-15 2008-02-21 Qian-Li Song West nile virus antigen and assay
US8241638B2 (en) * 2006-11-09 2012-08-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
WO2008118013A2 (en) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
EP2003144A1 (en) * 2007-06-15 2008-12-17 Institut Pasteur Method for the diagnosis or the screening of an arbovirus infection, reagents useful in said method and their applications
WO2009024534A2 (en) * 2007-08-17 2009-02-26 Intercell Ag Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
US8138318B2 (en) * 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
MX2010007461A (es) * 2008-01-11 2010-10-20 VGX Pharmaceuticals LLC Nuevas vacunas contra multiples subtipos del virus del dengue.
WO2009098277A1 (en) * 2008-02-08 2009-08-13 Intercell Ag Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
WO2009130261A1 (en) * 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
CN101333246B (zh) * 2008-07-30 2011-04-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用
MX2011002071A (es) 2008-08-29 2011-04-05 Boehringer Ingelheim Vetmed Vacuna para el virus del nilo occidental.
CN101607983B (zh) * 2009-07-29 2012-06-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒PrM/M蛋白B细胞抗原表位多肽及应用
CA2973863C (en) 2009-07-31 2022-05-17 Ge Healthcare Bio-Sciences Corp. High yield yellow fever virus strain with increased propagation in cells
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
EP2571990A4 (en) * 2010-05-21 2013-11-20 Univ Pittsburgh UNIVERSAL DENGUE VIRUS SEQUENCES AND METHOD FOR THEIR USE
AR079970A1 (es) * 2010-07-23 2012-02-29 Xcellerex Inc Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
CA2829226C (en) 2011-03-14 2023-01-03 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
US20140286983A1 (en) 2011-10-20 2014-09-25 The Government of the USA as represented by the Secretaryof the Dept. of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
SG11201500439RA (en) * 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
CN104630160B (zh) * 2015-01-23 2018-04-27 中国农业科学院哈尔滨兽医研究所 表达西尼罗热病毒PrM/E蛋白的重组新城疫LaSota疫苗株
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
ES2937963T3 (es) * 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
BR112018075513A2 (pt) 2016-06-13 2019-10-01 Us Health ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
US20180028643A1 (en) * 2016-06-21 2018-02-01 Brock Adam Kingstad-Bakke Zika virus vaccines using virus-like particles
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
EP4043031A3 (en) * 2016-11-17 2022-11-23 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
US11292816B2 (en) 2018-02-22 2022-04-05 Euroimmun Medizinische Labordiagnostika Ag Assay for the diagnosis of viral infections
EP3530668A1 (en) * 2018-02-22 2019-08-28 Euroimmun Medizinische Labordiagnostika AG A novel assay for the diagnosis of viral infections
CN113651885B (zh) * 2018-04-04 2022-04-15 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN108904793B (zh) * 2018-07-29 2021-03-30 首都医科大学附属北京友谊医院 预防流行性乙型脑炎的dna疫苗及其构建方法
US20220054620A1 (en) * 2018-12-20 2022-02-24 The Wistar Institute Of Anatomy And Biology Vaccines against powassan virus, and methods of using same
WO2021127580A1 (en) * 2019-12-18 2021-06-24 Maslow Joel Powassan viral antigens and related compositions, and uses thereof to vaccinate and treat patients
KR102216078B1 (ko) * 2020-04-22 2021-02-16 국방과학연구소 유전자 백신으로 사용하기 위한 항원 유전자 전달용 발현 벡터 및 이를 포함하는 유전자 백신
US20230272405A1 (en) * 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor
WO2024097725A1 (en) * 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (ja) 1968-10-17 1970-08-24
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPS634895A (ja) 1986-06-24 1988-01-09 Mitsubishi Electric Corp オゾン精製水供給装置
JPS63105682A (ja) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp デングウイルス３型由来のｃＤＮＡ
FR2614219B1 (fr) 1987-04-23 1993-07-09 Materiels Annexes Dialyse Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre.
JPH084508B2 (ja) * 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US4783502A (en) 1987-12-03 1988-11-08 Ppg Industries, Inc. Stable nonaqueous polyurethane microparticle dispersion
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
JPH0425408A (ja) 1990-05-21 1992-01-29 Hitachi Ltd ペレタイジングシステムの自動連続運転制御方法
FR2665710A1 (fr) 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2254055T3 (es) * 1991-09-19 2006-06-16 The United States Of America, As Represented By The Secretary, Departm. Of Health And Human Services Flavivirus quimericos y/o de crecimiento restringido.
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
JPH07265093A (ja) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
WO1996037221A1 (en) 1995-05-24 1996-11-28 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
CZ300172B6 (cs) * 1997-02-28 2009-03-04 Acambis Inc. Chimerický živý, infekcní, oslabený virus, lécivopro prevenci nebo lécbu flavivirových infekcí s jeho obsahem a molekula nukleové kyseliny jej kódující
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
ATE321567T1 (de) 1997-07-31 2006-04-15 Hawaii Biotech Inc Rekombinante dimerische hüllproteine als impfstoff gegen eine flavivirale infektion
ATE316796T1 (de) 1997-11-20 2006-02-15 Us Army Medical Res And Materi Dna impfstoffe gegen zecken-flavivieren
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP4489943B2 (ja) 1998-06-04 2010-06-23 アメリカ合衆国 フラビウイルス感染の予防のための核酸ワクチン
AU2002305028A1 (en) 2001-02-28 2002-10-28 Brown University Research Foundation West nile virus epitopes and uses thereof
CA2440593A1 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides

Similar Documents

Publication Publication Date Title
JP2010017185A5 (ja)
Martínez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
CN111902163B (zh) 使用重组复制子系统诱导和增强免疫应答
JP2004532023A5 (ja)
JP6797275B2 (ja) フラビウイルスワクチン接種のための組成物及び方法
JP2016501015A5 (ja) デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
JP2008529558A5 (ja)
JP2008508859A5 (ja)
JP2013542224A5 (ja)
JP2010522540A5 (ja)
JP2009504654A5 (ja)
JP2010057496A (ja) キメラフラビウイルスワクチン
FI3539565T3 (fi) Koostumuksia ja menetelmiä dengue-viruksen kimeerisille rakenteille rokotteissa
JP2014513952A5 (ja)
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
JP2016504315A5 (ja)
WO2018152526A1 (en) Zika virus vaccines
Faheem et al. A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies
JP2005510244A5 (ja)
ES2637629T3 (es) Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
JP2018502080A5 (ja)
JP2019535291A5 (ja)
JP2006325595A5 (ja)
JP2009232836A5 (ja)
JP2012501351A5 (ja)